Search results
Results from the WOW.Com Content Network
Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), [10] [11] and immunoglobulin E-mediated food allergy. [12]
The US Food and Drug Administration on Friday approved a medication called Xolair to help lessen the severity of an accidental allergic reaction in people who are allergic to multiple foods.
The injectable drug was approved in 2003 under the name Xolair for chronic hives and allergic asthma, but now there was evidence it could also protect against severe allergic reactions to food ...
Lighter Side. Medicare. ... 165 children and adolescents who received injections of the drug Xolair were able to consume higher doses of the foods without triggering an allergic reaction, compared ...
The most common side effects reported by the European Medicines Agency (EMA) include injection-site reactions (such as redness, swelling including due to fluid build-up, itching and pain), conjunctivitis (redness and discomfort in the eye) including conjunctivitis due to allergy, joint pain, cold sores, and increased blood levels of a type of ...
Injection site reactions (ISRs) are reactions that occur at the site of injection of a drug. They may be mild or severe and may or may not require medical intervention. Some reactions may appear immediately after injection, and some may be delayed. [1] Such reactions can occur with subcutaneous, intramuscular, or intravenous administration.
Xolair, a 20-year-old asthma drug sold by Roche and Novartis, significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on ...
Common side effects in clinical trials included headache (19% of patients under mepolizumab treatment versus 18% under placebo), injection site reactions (8% versus 3%), infections of the urinary tract (3% versus 2%) and the lower respiratory tract, eczema and muscle spasms (both 3% versus <1%).